

**Curriculum Vitae**  
**David Leonard Johnson, M. D.**  
**Palmetto Retina Center, LLC**  
**124 Sunset Court**  
**West Columbia, SC 29169**

**EDUCATION:**

- 2006-2008 Fellowship in Vitreoretinal Diseases and Surgery,  
University of Wisconsin, Madison, WI.
- 2003-2006 Resident in Ophthalmology, University of South Carolina School  
of Medicine, Columbia, SC.
- 2002-2003 Internship in Internal Medicine, University of South Carolina School  
of Medicine, Columbia, SC.
- 1998-2002 University of South Carolina School of Medicine, Columbia, SC.  
Medical Degree
- 1994-1998 Presbyterian College, Clinton, SC.  
Bachelor of Science, Major: Biology

**PROFESSIONAL EXPERIENCE:**

- 2008-Present Palmetto Retina Center, LLC, West Columbia, SC.
- 2012-Present Clinical Assistant Professor, Department of Ophthalmology  
Palmetto Health, Columbia, SC
- 2006-2008 Attending Physician, VA Medical Center, Madison, WI.
- 2006-2008 Clinical Assistant Professor, Department of Ophthalmology,  
University of Wisconsin, Madison, WI.
- 2005-2006 Contract Physician, Dorn VA Medical Center, Columbia, SC.  
Ophthalmology Division.

**PROFESSIONAL CERTIFICATIONS:**

- 2008 American Board of Ophthalmology  
2003 United States Medical Licensing Examinations

## **LICENSES:**

South Carolina Board of Medical Examiners, 2002.

South Carolina Drug Enforcement Agency, 2002.

United States Drug Enforcement Agency, 2002.

Wisconsin Board of Medical Examiners, 2006.

## **CLINICAL RESEARCH:**

March 2015 – present Investigator. A Multi-Center, Two-Stage, Open-Label Phase I and Randomized, Active Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology Compared with Eylea® for the Treatment of Recurrent Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Protocol: NT-503-3-AMD-001 Sponsor: Neurotech

February 2015 – present Investigator. A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients with Neovascular Age-Related Macular Degeneration Protocol: R2176-3-AMD-1417 (CAPELLA) Sponsor: Regeneron

September 2014 – present Investigator. Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a multicenter, prospective, randomized non-inferiority trial of eyes with macular edema secondary to central retinal vein occlusion, comparing Intravitreal Bevacizumab every 4 weeks with Intravitreal Aflibercept every 4 weeks.

May 2014 – present Investigator. Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery Protocol: C-12-067 Sponsor: Alcon

March 2014 – present Investigator. A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects with Diabetic Macular Edema Protocol: AKB-9778-CI-2003 (TIME 2) Sponsor: Aerpio

May 2013 – 2015 A Randomized, Placebo-Controlled, Parallel, Double-Masked Study To Evaluate The Efficacy And Safety Of Two Doses Of Oral Optina™ In Adult Patients With Diabetic Macular Edema Protocol: AP-05-002 (OPTINA) Sponsor: Ampio

May 2013 – 2014 A Prospective, Randomized, Double-Masked, Multicenter, Two Arm Study Comparing the Efficacy and Safety of ESBA 1008 versus EYLEA® in Subjects with Exudative Age-Related Macular Degeneration Protocol: C-12-006 (OSPREY) Sponsor: Alcon

2011-present Diabetic Retinopathy Clinical Research Network: Effect of Diabetes Education during Retinal Ophthalmology Visits on Diabetes Control. Protocol M

2011-present A Phase 2a, Multi-center , Masked, Randomized, Comparator-controlled Study Evaluating iSONEP(Sonepcizumab LT 1009) as Either Monotherapy or Adjunctive Therapy to Lucentis or Avastin Versus Lucentis or Avastin Alone for the treatment of Subjects with Choroidal Neovascularization Secondary to Age-related Macular Degeneration (Nexus). Sponsor LPath

2012-present An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients with Neovascular Age-Related Macular Degeneration (1124). Sponsor: Regeneron

2013-present TReat And exteNd therapy usinG intravitrEal aflibercept for previously treated patients exiting wet age-related macular degeneration extension study (0910) (RANGE).

2013-present A phase IIIb, multicenter, randomized, controlled study of the safety, tolerability and efficacy of intravitreal injections of 0.5mg ranibizumab given monthly compared to a Treat and Extend protocol in patients with wet age-related macular degeneration (TRES AMD). Sponsor: Genentech

2013-present A Phase 3 Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreal Administration of Fovista (Anti-PDGF-B Pegylated Aptamer) Administered in Combination with Lucentis Compared to Lucentis Monotherapy in Subjects With Neovascular Age-Related Macular Degeneration (OPH1003) Sponsor: Ophthotech

2012-present Multi-Center Randomized, Single Masked Phase 2 Study of Intravitreal Injections of SIROLIMUS in the Treatment of Central Geographic Atrophy associated with Age- Related Macular Degeneration (SIROLIMUS). Sponsor: NEI

2011-present A phase III, multinational, multicenter, randomized, double-masked, study assessing the safety and efficacy of intravitreal injections of DE-109 (three doses) for the treatment of active, non-infectious uveitis of the posterior segment of the eye. Sponsor: Santen

2011-present Regeneron 1009.1 A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema (1009). Sponsor: Regeneron

2012-present A Multicenter, Open-Label, Randomized Study Comparing the Efficacy and Safety of 700ug Dexamethasone Posterior Segment Drug Delivery System(DEX PS DDS) to Ranibizumab in Patients with Diabetic Macular Edema (206207-024). Sponsor: Allergan

2012-present Diabetic Retinopathy Clinical Research Network: A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema. Protocol T

2012-2014 A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion (1027). Sponsor: Regeneron

2007-present Investigator. Age-related Eye Diseases Study 2 (AREDS2): A multi-center, randomized trial of lutein, zeaxanthin, and Omega-3 Long-Chain Polyunsaturated Fatty Acids (Docosahexaenoic Acid [DHA] and Eicosapentaenoic Acid [EPA]) in age-related macular degeneration . Sponsor: National Eye Institute

2007-2008 Investigator. A trial to assess the safety and tolerability of repeated doses of intravitreal administration of two VEGF trap formulations in subjects with neovascular age related macular degeneration. Sponsor: Regeneron

2007-2010 Investigator. A phase II multicenter, randomized, double-masked, placebo-controlled, dose-comparison study of the safety and efficacy of fenretinide in the treatment of geographic atrophy in subjects with age-related macular degeneration. Sponsor: Sirion

2007-2009 Investigator. A phase 3, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered 8 or 12 weeks as maintenance therapy following three injections of Lucentis® compared with Lucentis® monotherapy every 4 weeks in patients with exudative age-related macular degeneration.

2008-2010 Investigator. An open-label, long-term, safety, and tolerability study of intravitreal VEGF Trap-EYE in subjects with neovascular age-related macular degeneration. Sponsor: Regeneron

2008-present Investigator. Comparison of age-related macular degeneration treatment trials (CATT).

2009-present Investigator. The safety and efficacy of AL-8309B ophthalmic solution for the treatment of geographic atrophy secondary to age-related macular degeneration (GATE). Sponsor: Alcon

2010-present Investigator. A phase 2, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal injections of E10030 (anti-PDGF pegylated aptamer) given in combination with Lucentis® in subjects with neovascular age-related macular degeneration. Sponsor: Ophthotech.

2010- present Investigator. A Phase IIa, Safety and Preliminary Effects Study of WST11 (Stakel(r))-Mediated Vascular-Targeted Photodynamic (VTP) Therapy in Subjects with Choroidal Neovascularization (CNV) Associated with Age-Related Macular Degeneration (AMD). Sponsor: Steba

2011-present Investigator. A phase 1/2 trial to investigate the safety and tolerability of single and repeated doses of hI-CON™ following administration by intravitreal injection in subjects with neovascular age-related macular degeneration . Sponsor: Iconic

2005-2007 Investigator. An open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) who have completed the treatment phase of a Genentech sponsored ranibizumab study. Sponsor: Genentech

2005-2008 Investigator. A Phase IIIB, single-masked, multicenter, randomized study to evaluate the safety and tolerability of Ranibizumab in naive and previously treated subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Sponsor: Genentech

2007-2008 Investigator. DNA repository study in association with study FVF3426g (An open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) who have completed the treatment phase of a Genentech sponsored ranibizumab study)

2007-present Investigator. A phase III, double-masked, multi-center randomized, sham-controlled study of the efficacy and safety of ranibizumab injection in subjects with clinically significant macular edema with center involvement secondary to diabetes mellitus (RISE and RIDE). Sponsor: Genentech

2007-present Investigator. A randomized, double-masked, active-controlled phase III study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF trap in subjects with neovascular age-related macular degeneration. Sponsor: Regeneron

2008-2009 Investigator. A phase III, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to central retinal vein occlusion (CRUISE). Sponsor: Genentech

2008-2009 Investigator. A phase III, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to branch retinal vein occlusion (BRAVO). Sponsor: Genentech

2007-2009 Investigator. A 24-month randomized, double masked, controlled, multicenter, phase IIIB study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with ranibizumab (Lucentis™) versus ranibizumab (Lucentis™) monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (DENALI). Sponsor: Novartis

2008-2010 Investigator. A phase 2, randomized, double-masked, placebo-controlled, dose-ranging clinical study to assess the safety and efficacy of subconjunctival injections of sirolimus in patients with diabetic macular edema secondary to diabetic retinopathy. Sponsor: Macusight

2009-2011 Investigator. A double-masked, randomized, controlled study of the safety, tolerability and biological effect of repeated intravitreal administration of VEGF Trap-Eye in patients with diabetic macular edema (DME). Sponsor: Regeneron

2009-2011 Investigator. A randomized, double masked, controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in Subjects with macular edema secondary to central retinal vein occlusion (CRVO). Sponsor: Regeneron

2009-present Investigator. A phase III, double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5mg and 2.0mg ranibizumab administered monthly or on an as-needed basis (PRN) in patients with subfoveal neovascular age-related macular degeneration (HARBOR). Sponsor: Genentech

2010-present Investigator. A phase I, double-masked, placebo-controlled study evaluating the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple escalating dosages of RN6G in subjects with advanced dry, age-related macular degeneration (AMD) including geographic atrophy. Sponsor: Pfizer

2010 Investigator. VEGF Trap-Eye pharmacokinetic sub-study [HYPERLINK "http://VGFT-OD-0706.PK/"](http://VGFT-OD-0706.PK/)[VGFT-OD-0706.PK](http://VGFT-OD-0706.PK/). Sponsor: Regeneron

2010-present Investigator. DNA repository substudy in association with ranibizumab study FVF4579g: a phase III, double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5mg and 2.0mg ranibizumab administered monthly or on an as-needed basis (PRN) in patients with subfoveal neovascular age-related macular degeneration. Sponsor: Genentech

2011-present Investigator. A phase IB/II, multicenter, randomized, single-masked, sham injection-controlled study of safety, tolerability, and evidence of activity of FCFD4514S intravitreal injections administered monthly or every other month to patients with geographic atrophy. Sponsor: Genentech

2011-present Investigator. A multi-center randomized study evaluating dosing regimens for treatment with intravitreal ranibizumab injections in subjects with macular edema following retinal vein occlusion (SHORE). Sponsor: Genentech

2011-present Investigator. A phase III, multinational, multicenter, randomized, double-masked, study assessing the safety and efficacy of intravitreal injections of DE-109 (three doses) for the treatment of active, non-infectious uveitis of the posterior segment of the eye. Sponsor: Santen

## **PRESENTATIONS:**

Diabetes And Your Eyes. Presented at Annual Florence County Council on the Aging. March 2011.

Eye Disease in the Elderly Population. Presented at Orangeburg County Council on Aging. Orangeburg, SC. October 2008-2011.

Understanding Diabetic Retinopathy. Presented at the Annual African American Diabetes Conference, Department of Health and Environmental Control, Columbia, SC. November 2008-2009.

Update on Diagnosis and Treatment of Diabetic Retinopathy. Presented at the Annual Ophthalmology Update for Primary Care Practitioners, University of South Carolina School of Medicine, Columbia, SC. November 2008.

Acute Posterior Multifocal Placoid Pigment Epitheliopathy. Department of Ophthalmology, University of Wisconsin, Madison, WI. March 2008

White Dot Syndromes. Presented at Ophthalmic Technicians Continuing Nursing Education, University of Wisconsin, Madison, Wisconsin. January 2008.

Ocular Manifestations of Syphilis. Presented at American Society of Retina Specialists, Mentoring in Ophthalmology Fellowship Program, Palm Springs, California. December 2007.

Update on Vitreoretinal Surgical Techniques. University of Wisconsin Department of Ophthalmology, Madison, Wisconsin. August 2007.

OPHTEC Model 311 Artificial Iris Lens For the Treatment of Visual Disturbances Resulting From Partial or Total Absence of the Human Iris. Presented at Grand Rounds, University of Wisconsin, Madison, Wisconsin. February 2007.

Update on Diabetic Retinopathy. Department of Endocrinology, University of Wisconsin, Madison, Wisconsin. November 2006, September 2007.

Ocular Structural Changes During Microkeratome Suction Ring Placement in LASIK. Jason A. Evangelista, MD, Richard M. Davis, MD, David L. Johnson, MD. American Society of Cataract and Refractive Surgeons, San Francisco, California. April 2006.

Hyperbaric Oxygen Therapy and the Eye. David Johnson, MD. Department of Hyperbaric Medicine. Palmetto Richland Memorial Hospital, Columbia, South Carolina. Lecture Series, 2005-2006.

Demographics and Outcomes of Eye Trauma Victims in South Carolina. University of South Carolina School of Medicine, Department of Ophthalmology, Columbia, South Carolina. 2004.

Ocular Pharmacology and Toxicology of Fireworks Injuries. V.A. Pakalnis, R.C. Tripathi, D. Johnson. Department of Ophthalmology, University of South Carolina School of Medicine, Columbia, South Carolina. Presented at International Society of Ocular Toxicology, 2004.

Drug Induced Glaucomas. Ramesh Tripathi, MD, Brenda Tripathi, PhD, Chris Haggerty, MD, David Johnson, MD. Biannual Ophthalmology Update, Columbia, South Carolina. January 2003.

Examining Patient's Satisfaction With as Well as the Effectiveness of Using a Mobile Screening Unit With a Non-Mydriatic Fundoscopic Photography to Screen for Diabetic Retinopathy in a Rural Population. University of South Carolina School of Medicine, Department of Family Medicine, Department of Ophthalmology, Columbia, South Carolina. July 2001.

Examining Factors That Contribute to the High Rate of Missed Appointments in a Community Based Primary Care Practice and the Effect it has on Those Patients With Chronic Conditions That Require Close Follow Up. University of South Carolina School of Medicine, Department of Family Practice, Columbia, South Carolina. April 2001.



## **TEXTBOOK CHAPTERS:**

Optical Coherence Tomography. Michael Altaweel and David Johnson. Book Chapter in Principles and Practice of Ophthalmology, by Albert and Jakobiec, 4<sup>th</sup> Edition. Saunders Publishing, 2007.

## **PUBLICATIONS**

Central Serous Papillopathy, a Variant of Central Serous Chorioretinopathy. D Johnson, V Patel. *Journal of Neuro-Ophthalmology*: June 2009 - Volume 29 - Issue 2 - 155-156.

Rhegmatogenous Retinal Detachment After Laser Prophylaxis for Retinoschisis. D Johnson, J Nieto, M Ip. *Archives of Ophthalmology*. 2008;126(12):1775-1776.

Uveal Melanoma Masquerading as Pigment Dispersion Glaucoma. DL Johnson, M Altaweel, A Neekrha, D Albert. *Archives of Ophthalmology*. June 2008.

## **ABSTRACTS:**

Bevacizumab (Avastin®) Monotherapy For Exudative Age-related Macular Degeneration. J.L. Gottlieb, A.C. Breunig, D.L. Johnson. *Ophthalmology/Visual Science*, University of Wisconsin-Madison, Madison, WI. Madison, WI. Presented at ARVO, 2009.

Express Shunt Under a Scleral Flap as Primary Surgical Treatment for Open Angle Glaucomas. D.Johnson, C.Bair, J.Evangelista, R.Trespalacios, K.Mitchell, J.Frankel, R.Davis. ARVO 2006.

Express Shunt Under a Scleral Flap for Neovascular Glaucoma. J.A. Evangelista, D.L. Johnson, R.Trespalacios, J.Frankel. ARVO 2006.

Prophylactic Treatment of Pain in LASEK. R. Trespalacios, R.M. Davis, J. Evangelista, D. Johnson, D. Skufca. ARVO 2006.

Central Corneal Thickness Changes After Goldmann Applanation Tonometry and Gonioscopy. J.A. Evangelista, J.H. Oakman, D.L. Johnson, J.P. Tao, R.Trespalacios, A.D. Hitch. ARVO 2005.

Are Patients With Diabetes Less Likely to Develop Age-Related Macular Degeneration if Panretinal Photocoagulation Was Performed? Follow Up to the Biomechanical Shell Model Hypothesis. D.Johnson, J.Evangelista, R.Trespalacios, R.Peddada, B.Bray, V.Pakalnis, R.Davis. ARVO 2005.

## **EDITORIAL REVIEW BOARD:**

Retina, August 2006-Present.

Ophthalmology, November 2006-Present.

British Journal of Ophthalmology, August 2006-Present.  
Archives of Ophthalmology, August 2006-Present.

### **AWARDS AND HONORS:**

Mentoring in Ophthalmology Fellows Educational Program, American Society of Retina Specialists, November 2007.  
Chief Resident, 2005-2006.  
Cum Laude, 2002.  
Magna Cum Laude, 1998.  
Dean's List, Presbyterian College, 1994-1998.  
President's List, Presbyterian College, 1994-1997.  
Olmert Scholarship, 1997.  
SCANA Scholarship, 1997.  
Junior Graduation Marshall, 1997.  
Sigma Kappa Alpha Honor Society, 1995.  
Beta Beta Beta Honors Biology Society, 1995.

### **MEMBERSHIP IN PROFESSIONAL SOCIETIES:**

American Society of Retinal Specialists, 2007-Present.  
Madison Ophthalmology Society, 2006-2008.  
Association for Research in Vision and Ophthalmology, 2003-Present.  
South Carolina Ophthalmology Society, 2003-Present..  
Central South Carolina Ophthalmological Society, 2003-Present.  
American Academy of Ophthalmology, 2003-Present.  
University of South Carolina School of Medicine Alumni Association, 2002-Present.  
South Carolina Medical Association, 1998-Present.  
American Medical Association, 1998-Present.  
Flying Physicians Association, 1998-Present.  
Aircraft Owners and Pilots Association, 1996-2006.

### **COMMUNITY SERVICE:**

Glaucoma and Diabetic Eye Screening. Annual Florence County Council on Aging. Florence, SC, March 2011.  
Annual World Sight Community Eye Clinic, Madison, WI, 2006-2007.  
South Carolina Rural Diabetic Eye Screening, Columbia, SC, 2001-2006.  
The Free Medical Clinic, Columbia, SC, 1998-2006.

